文献速递消化系统肿瘤

索拉非尼起始剂量对肝细胞癌治疗的影响:回顾性多机构研究

Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.
PubMed 文献 · J Clin Oncol · 2017-09-05

该回顾性多机构研究纳入2006年至2015年间128家退伍军人健康管理医院中4903例接受索拉非尼治疗的肝细胞癌患者,比较标准起始剂量(800 mg/d)与降低起始剂量(<800 mg/d)的疗效与费用。

要点

  • 降低索拉非尼起始剂量未显示总生存劣于标准剂量(调整后HR 0.92,95%CI 0.83-1.01)。
  • 降低起始剂量组总累积索拉非尼费用显著低于标准剂量组。

核心结论

  • 降低索拉非尼起始剂量与减少药片负担、降低治疗费用及因不良事件停药率下降的趋势相关,且未显示总生存劣于标准剂量。

研究设计与样本

  • 回顾性多机构研究,纳入2006年1月至2015年4月期间128家退伍军人健康管理医院中4903例因肝细胞癌接受索拉非尼治疗的患者,采用1:1倾向性评分匹配及Cox回归分析,主要终点为总生存。

主要发现

  • 标准起始剂量组3094例(63%),降低起始剂量组1809例(37%)。
  • 降低起始剂量组中位总生存低于标准剂量组(200天 vs 233天,HR=1.10)。

关键数值与推荐

  • 标准起始剂量定义为索拉非尼800 mg/d口服;降低起始剂量定义为<800 mg/d口服。
  • 非劣效界值为HR=1.1。

临床怎么用

  • 对于肝细胞癌患者,索拉非尼起始剂量降低至<800 mg/d未显示总生存劣于标准剂量800 mg/d,且与更低的药物费用和因胃肠道不良反应停药率相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Sorafenib is currently the only Food and Drug Administration-approved first-line therapy for patients with advanced hepatocellular carcinoma. There are few data examining how sorafenib starting dose may influence patient outcomes and costs. Patients and Methods We retrospectively evaluated 4,903 patients from 128 Veterans Health Administration hospitals who were prescribed sorafenib for hepatocellular carcinoma between January 2006 and April 2015. After 1:1 propensity score matching to account for potential treatment bias, hazard ratios (HRs) were calculated using Cox regression and were tested against a noninferiority margin of HR = 1.1. A matched multivariate logistic regression was performed to adjust for potential confounders. The primary end point was overall survival (OS) of patients who were prescribed standard starting dosage sorafenib (800 mg/d per os) versus that of patients who were prescribed reduced starting dose sorafenib (< 800 mg/d per os). Results There were 3,094 standard dose sorafenib patients (63%) and 1,809 reduced starting dose sorafenib patients (37%). Reduced starting dose sorafenib patients had more Barcelona Clinic Liver Cancer stage D ( P < .001), higher Model for End-Stage Liver Disease Sodium scores ( P < .001), higher Child-Turcotte-Pugh scores ( P < .001), and higher Cirrhosis Comorbidity Index scores ( P = .01). Consequently, reduced starting dose sorafenib patients had lower OS (median, 200 v 233 days, HR = 1.10). After propensity score matching and adjusting for potential confounders, there was no longer a significant OS difference (adjusted hazard ratio [HRadj], 0.92; 95% CI, 0.83 to 1.01), and this fell significantly below the noninferiority margin ( P < .001). Reduced starting dose sorafenib patients experienced significantly lower total cumulative sorafenib cost and were less likely to discontinue sorafenib because of gastrointestinal adverse effects (8.7% v 10.8%; P = .047). Conclusion The initiation of sorafenib therapy at reduced dosages was associated with reduced pill burden, reduced treatment costs, and a trend toward a decreased rate of discontinuing sorafenib because of adverse events. Reduced dosing was not associated with inferior OS relative to standard dosing.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Reiss KA, Yu S, Mamtani R, et al. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol. 2017. PMID: 28872925. doi:10.1200/JCO.2017.73.8245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。